DENGVAXIA, manufactured by Sanofi Pasteur, is a live, genetically modified dengue virus vaccine that contains the pre-membrane (prM) and Envelope (E) genes from each of the four wild-type dengue viruses, as well as the capsid gene and the replication genes from attenuated Yellow Fever (YF) 17D strain virus (virus vector vaccine).
Each 0.5 mL dose of DENGVAXIA dengue vaccine contains each of the chimeric yellow fever dengue (CYD) virus serotypes 1, 2, 3, and 4. The vaccine also contains 2 mg of sodium chloride, 2.5 mg L-arginine hydrochloride, 0.56 mg essential amino acids (including L-phenylalanine), 0.2 mg non-essential amino acids, 9.38 mg D-sorbitol, 18.75 mg sucrose, 13.75 mg D-trehalose dihydrate, 0.18 mg trometamol, and 0.63 mg urea.
The four CYD viruses (CYD-1, CYD-2, CYD-3, and CYD-4) in DENGVAXIA were created by using recombinant DNA technology that replaced the sequences encoding the pre-membrane (prM) and envelope (E) proteins in the yellow fever (YF) 17D204 vaccine virus genome with those encoding for dengue virus serotypes 1, 2, 3, and 4, respectively. Each CYD virus is cultured individually in Vero cells (African Green Monkey kidney), harvested from the Vero cells and subsequently purified through membrane chromatography and ultrafiltration. The concentrated and purified harvest of each CYD virus is then diluted in a stabilizer solution. The final bulk product is sterilized, filled into vials and freeze-dried. DENGVAXIA dengue vaccine does not contain a preservative.
DENGVAXIA is recommended as a 3-dose series given subcutaneously six months apart.
